Masayasu Ukai

Dr. Masayasu Ukai

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
MUMasayasu Ukai
Masayasu Ukai
TPThomas Parmentier
Thomas Parmentier
MCMiguel A. Cortez
Miguel A. Cortez
AFAndrea Fischer
Andrea Fischer
LGLuis Gaitero
Luis Gaitero
FJFiona James
Fiona James
Background Many studies of epilepsy in veterinary medicine use subjective data (eg, caregiver‐derived histories) to determine seizure frequency. Conversely, in people, objective data from electroencephalography (EEG) are mainly used to diagnose epilepsy, measure seizure frequency and evaluate efficacy of antiseizure drugs. These EEG data minimize the possibility of the underreporting of seizures, a known phenomenon in human epileptology. Objective To evaluate the correlation between reported seizure frequency and EEG frequency of ictal paroxysmal discharges (PDs) and to determine whether seizure underreporting phenomenon exists in veterinary epileptology. Animals Thirty‐three ambulatory video‐EEG recordings in dogs showing ≥1 ictal PD, excluding dogs with status epilepticus. Methods Retrospective observational study. Ictal PDs were counted manually over the entire recording to obtain the frequency of EEG seizures. Caregiver‐reported seizure frequency from the medical record was categorized into weekly, daily, hourly, and per minute seizure groupings. The Spearman rank test was used for correlation analysis. Results The coefficient value (rs) comparing reported seizure to EEG‐confirmed ictal PD frequencies was 0.39 (95% confidence interval [CI] = 0.048‐0.64, P = .03). Other rs values comparing history against various seizure types were: 0.36 for motor seizures and 0.37 for nonmotor (absence) seizures. Conclusions and Clinical Importance A weak correlation was found between the frequency of reported seizures from caregivers (subjective data) and ictal PDs on EEG (objective data). Subjective data may not be reliable enough to determine true seizure frequency given the discrepancy with EEG‐confirmed seizure frequency. Confirmation of the seizure underreporting phenomenon in dogs by prospective study should be carried out.

7 November 2017 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Closed access
MUMasayasu Ukai
Masayasu Ukai
YHYuji Hamamoto
Yuji Hamamoto
YYYoshihiko Yu
Yoshihiko Yu
AFAki Fujiwara-Igarashi
Aki Fujiwara-Igarashi
MFMichio Fujita
Michio Fujita
DHDaisuke Hasegawa
Daisuke Hasegawa
Objectives: The effectiveness of zonisamide (ZNS) against spontaneous epilepsy in cats has not yet been described. The purpose of this study was to investigate the effect of ZNS on interictal paroxysmal discharges (PDs) using scalp electroencephalography (EEG) in familial spontaneous epileptic cats (FSECs). Methods: Eight FSECs were evaluated (six males and two females). Scalp EEG measurements were performed once a week for 3 weeks before ZNS administration (Pre-ZNS). Thereafter, administration of ZNS was started and an adjustment period was instituted until the drug in plasma achieved the steady state. When ZNS in plasma was confirmed to be within 10–40 μg/ml, scalp EEG measurements were performed once a week for 3 weeks (Post-ZNS). The number of PDs (counts/min) were compared between Pre-ZNS and Post-ZNS treatment. Results: The median number of PDs for Pre-ZNS and Post-ZNS were 0.43/min (0.13–0.82/min) and 0.28/min (0.07–0.87/min), respectively. The number of PDs Post-ZNS was significantly reduced compared with Pre-ZNS ( P = 0.02). Conclusions and relevance: This study showed that ZNS, within the recommended therapeutic range suggested for use in humans and dogs (10–40 µg/ml), reduced the number of PDs recorded on EEG in FSECs that are considered a model for cats with idiopathic epilepsy. Although phenobarbital is the antiepileptic drug of choice for epileptic cats, the results of this research provide evidence to support the use of ZNS in cats with phenobarbital-resistant epilepsy or for cats that cannot use phenobarbital due to adverse side effects.

5 August 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
MUMasayasu Ukai
Masayasu Ukai
JKJade Kurihara
Jade Kurihara
MAMarkos Antonakakis
Markos Antonakakis
KBKrista Banks
Krista Banks
SDSteven Dow
Steven Dow
SMStephanie McGrath
Stephanie McGrath
Glioma is a type of neoplasia that spontaneously arises from the glial cells of the brain in humans and dogs, and its prognosis is grave. Current treatment options for glioma include surgery, radiation therapy, chemotherapy, or symptomatic treatment. Evidence has shown that cannabidiol (CBD) may have anticancer, anti-angiogenic, and anti-inflammatory properties in both in vitro and in vivo studies. In this in vivo murine experiment, the canine glioma cell line J3TBG was injected into the frontoparietal cortex of immunodeficient mice using xenogeneic tissue transplantation. A total of 20 mice were randomly assigned to one of four treatment groups—Control group (C), CBD group (CBD), Radiation Therapy group (RT), and CBD plus Radiation Therapy group (CBD + RT). After transplantation of J3TBG, a single fraction of 5.5 Gy RT was administered to the RT and CBD + RT groups, and CBD was administered daily to the CBD and CBD + RT groups. Necropsies were performed to collect blood and brain tissue. Although there was not a statistically significant difference, the survival time among mice were longer in the CBD + RT group than the RT group. These results indicate that CBD may be used as an adjunctive therapy to enhance RT treatment. Larger cohort studies are required to substantiate the hypothesis.

2 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
MUMasayasu Ukai
Masayasu Ukai
ABAgnieszka Z. Burzynska
Agnieszka Z. Burzynska
JMJulie Ann Moreno
Julie Ann Moreno
CLCaitlin Latimer
Caitlin Latimer
JHJamie Henry
Jamie Henry
SMStephanie McGrath
Stephanie McGrath
Background Canine cognitive dysfunction (CCD) is a progressive neurodegenerative condition in aging dogs that mimics Alzheimer’s disease in humans. While diffusion tensor imaging (DTI) has been used to study white matter changes in human dementia, its role in CCD diagnosis remains unclear. Methods 59 dogs classified into Young (n = 18), Aged (n = 17) and CCD (n = 24) based the Canine Dementia Scale (CADES). DTI data were collected, creating fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AxD) and radial diffusivity (RD) in four brain regions (corpus callosum, thalamus, internal capsule, hippocampus). All DTI variables were compared among the groups, and correlation between DTI variables and CADES and the Canine Cognitive Dysfunction Rating Scale (CCDR) was evaluated. When available, histopathological examination of the brain was performed to confirm CCD. Results Fifty-nine dogs were prospectively categorized into Young (n = 18), Aged (n = 17), and CCD (n = 24) groups. DTI data (FA, MD, AxD, RD) were extracted from the corpus callosum, thalamus, internal capsule, and hippocampus. Significant group differences were found in all DTI metrics for the corpus callosum, thalamus, and internal capsule, but not the hippocampus, with emphasis on FA in the corpus callosum in CCD dogs and aged dogs (P = .049). Significant negative correlation was identified between CADES and FA in the corpus callosum, thalamus and internal capsule. Postmortem analysis of seven brains showed increased neuroinflammatory morphology (hypertrophic astrocytes, ramified microglia) and tau phosphorylation (T217, T231). A loss of the luxol fast blue stain in the frontal cortex and thalamus was identified but not in hippocampus. Conclusions DTI revealed region-specific microstructural alterations in aging and CCD-affected dogs, particularly in white matter-rich regions like the corpus callosum. FA reductions were associated with both age and cognitive decline severity, supporting its use as a potential imaging biomarker. Histopathology corroborated the presence of neuroinflammation and myelin degradation, further validating the imaging findings. Together, these results support DTI as a promising non-invasive tool for the objective diagnosis and longitudinal monitoring of CCD, with potential translational relevance for human neurodegenerative disease research.